ENVARSUS XR Drug Patent Profile

Which patents cover Envarsus Xr, and what generic alternatives are available?

Envarsus Xr is a drug marketed by Veloxis Pharms Inc and is included in one NDA. There are ten patents protecting this drug and one Paragraph IV challenge.

This drug has thirty patent family members in sixteen countries.

The generic ingredient in ENVARSUS XR is tacrolimus. There are twenty drug master file entries for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the tacrolimus profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Envarsus Xr

A generic version of ENVARSUS XR was approved as tacrolimus by SANDOZ on August 10^th, 2009.

Summary for ENVARSUS XR

International Patents:	30
US Patents:	10
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	52
Drug Prices:	Drug price information for ENVARSUS XR
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ENVARSUS XR
DailyMed Link:	ENVARSUS XR at DailyMed

See drug prices for ENVARSUS XR

Recent Clinical Trials for ENVARSUS XR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Massachusetts General Hospital	PHASE4
Veloxis Pharmaceuticals	PHASE4
University Hospital, Limoges	PHASE4

See all ENVARSUS XR clinical trials

Pharmacology for ENVARSUS XR

Drug Class	Calcineurin Inhibitor Immunosuppressant
Mechanism of Action	Calcineurin Inhibitors

Paragraph IV (Patent) Challenges for ENVARSUS XR

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ENVARSUS XR	Extended-release Tablets	tacrolimus	0.75 mg, 1 mg and 4 mg	206406	1	2022-03-31

US Patents and Regulatory Information for ENVARSUS XR

ENVARSUS XR is protected by fifteen US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Veloxis Pharms Inc	ENVARSUS XR	tacrolimus	TABLET, EXTENDED RELEASE;ORAL	206406-003	Jul 10, 2015		RX	Yes	Yes	8,664,239
Veloxis Pharms Inc	ENVARSUS XR	tacrolimus	TABLET, EXTENDED RELEASE;ORAL	206406-003	Jul 10, 2015		RX	Yes	Yes	10,166,190		Y
Veloxis Pharms Inc	ENVARSUS XR	tacrolimus	TABLET, EXTENDED RELEASE;ORAL	206406-002	Jul 10, 2015		RX	Yes	No	9,549,918		Y
Veloxis Pharms Inc	ENVARSUS XR	tacrolimus	TABLET, EXTENDED RELEASE;ORAL	206406-002	Jul 10, 2015		RX	Yes	No	12,403,095		Y

Expired US Patents for ENVARSUS XR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Veloxis Pharms Inc	ENVARSUS XR	tacrolimus	TABLET, EXTENDED RELEASE;ORAL	206406-001	Jul 10, 2015	9,161,907
Veloxis Pharms Inc	ENVARSUS XR	tacrolimus	TABLET, EXTENDED RELEASE;ORAL	206406-002	Jul 10, 2015	8,623,410
Veloxis Pharms Inc	ENVARSUS XR	tacrolimus	TABLET, EXTENDED RELEASE;ORAL	206406-001	Jul 10, 2015	8,586,084
Veloxis Pharms Inc	ENVARSUS XR	tacrolimus	TABLET, EXTENDED RELEASE;ORAL	206406-002	Jul 10, 2015	9,763,920

EU/EMA Drug Approvals for ENVARSUS XR

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Astellas Pharma Europe B.V.	Modigraf	tacrolimus	EMEA/H/C/000954Prophylaxis of transplant rejection in adult and paediatric, kidney, liver or heart allograft recipients.Treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult and paediatric patients.	Authorised	no	no	no	2009-05-15
Astellas Pharma Europe BV	Advagraf	tacrolimus	EMEA/H/C/000712Prophylaxis of transplant rejection in adult kidney or liver allograft recipients.Treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult patients.	Authorised	no	no	no	2007-04-23
Chiesi Farmaceutici S.p.A.	Envarsus	tacrolimus	EMEA/H/C/002655Prophylaxis of transplant rejection in adult kidney or liver allograft recipients. Treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult patients.	Authorised	no	no	no	2014-07-18
LEO Pharma A/S	Protopic	tacrolimus	EMEA/H/C/000374Flare treatmentAdults and adolescents (16 years of age and above)Treatment of moderate to severe atopic dermatitis in adults who are not adequately responsive to or are intolerant of conventional therapies such as topical corticosteroids.Children (two years of age and above)Treatment of moderate to severe atopic dermatitis in children (two years of age and above) who failed to respond adequately to conventional therapies such as topical corticosteroids.Maintenance treatmentMaintenance treatment of moderate to severe atopic dermatitis for the prevention of flares and the prolongation of flare-free intervals in patients experiencing a high frequency of disease exacerbations (i.e. occurring four or more times per year) who have had an initial response to a maximum of six weeks treatment of twice daily tacrolimus ointment (lesions cleared, almost cleared or mildly affected).	Authorised	no	no	no	2002-02-27

International Patents for ENVARSUS XR

See the table below for patents covering ENVARSUS XR around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	081520
Canada	2688381
Canada	2729948
Denmark	2167033

Last updated: June 16, 2026

ENVARSUS XR Market Dynamics and Financial Trajectory (2026 Update)

ENVARSUS XR (Envarsus XR; extended-release tacrolimus) remains a niche but high-value brand positioned against generic tacrolimus immediate-release capsules and other extended-release tacrolimus products. Its market trajectory is driven by (1) transplant patient conversion from immediate-release tacrolimus to Envarsus XR, (2) payer reimbursement and pharmacy benefit design, (3) uptake and pricing pressure from extended-release competitors, and (4) the extent of patent and exclusivity-driven protection in the US and key markets.

The financial path is typically characterized by steady share retention in the converted cohort, then margin compression as PBM formularies tighten and generic or lower-cost substitutes expand. For investment and licensing decisions, the core drivers to underwrite are: net price dynamics (rebate and pass-through intensity), channel mix (specialty pharmacy vs retail), and durability of payer preference under competitive tendering.

---

What is ENVARSUS XR (Envarsus XR) and how does it generate revenue in transplant markets?

Featured snippet answer: Envarsus XR is an extended-release tacrolimus brand used to prevent organ rejection in kidney transplant recipients. Revenue is generated through specialty distribution to transplant patients with payer coverage that favors extended-release tacrolimus formulations.

Indication and clinical positioning

Envarsus XR is used as part of immunosuppressive regimens in kidney transplant recipients. Its commercial positioning is anchored to extended-release dosing convenience and adherence-related outcomes relative to tacrolimus immediate-release products. In practice, conversion is funded by payers and provider systems where adherence improvements and reduced variability are expected to lower clinical and administrative burden.

Revenue model: specialty channel economics

ENVARSUS XR typically sells through a specialty ecosystem with:

• Higher gross-to-net adjustments due to payer rebates and patient assistance structures.
• Ongoing marketing and field access costs in transplant centers.
• Contracting leverage influenced by competitor inventory, formulary status, and therapeutic interchange policies.

Core revenue levers used by brand management

• Patient conversion rate from tacrolimus immediate-release to Envarsus XR.
• Persistence and dose stability in maintenance regimens.
• Formulary placement durability (commercial PBMs and Medicare Part D).
• Net price after rebates, chargebacks, and channel incentives.

---

Who are the main competitors to ENVARSUS XR and how do they affect pricing power?

Featured snippet answer: Competitive pressure comes from generic tacrolimus immediate-release products and other extended-release tacrolimus brands, which constrain Envarsus XR net pricing through formulary competition and substitution policies.

Tacrolimus competitive set (mechanism and interchange)

• Immediate-release tacrolimus generics compete on acquisition cost.
• Extended-release tacrolimus competitors compete on payer preference, dosing profile, and perceived adherence or trough-stability advantages.

Payer dynamics that swing formulary status

Envarsus XR’s market share is sensitive to:

• PBM step therapy and prior authorization requirements.
• Payer willingness to pay for extended-release vs generic immediate-release.
• Health system contracting that bundles immunosuppression with transplant services.
• Switching protocols that may allow or discourage interchange at the patient level.

What typically happens to net revenue when competitors expand

When extended-release peers gain preferred status or when generics increase penetration, Envarsus XR tends to see:

• Net price erosion via rebate demands.
• Mix shift toward higher-discount contracting channels.
• Slower conversion in new-to-therapy cohorts.

---

When does ENVARSUS XR lose exclusivity and what is the generic entry risk timeline?

Featured snippet answer: Generic entry risk depends on patent expiry, Orange Book listed protection, and whether Paragraph IV ANDA challenges target formulation or method-of-use claims. The generic threat typically becomes more acute during the run-up to the latest-expiring relevant US patent or exclusivity trigger.

Exclusivity and patent strategy: what matters commercially

For a long-running immunosuppressant brand, the generic entry risk is usually driven by:

• Latest-expiring formulation patents covering the extended-release composition and release kinetics.
• Method-of-use patents tied to dosing regimens or therapeutic monitoring.
• Process/manufacturing patents affecting how extended-release tablets are made.
• Any relevant new formulation or new strength protections that can delay generic substitution.

How entry risk translates into financial trajectory

• Pre-expiry: steady revenue with higher discounting in contracting.
• Early post-expiry: revenue declines in the most substitutable segments.
• Later post-expiry: stabilization if payer policies or clinician switching barriers persist, and if generic products face uptake constraints tied to therapeutic monitoring and trough stability.

---

What patents protect ENVARSUS XR and which claim types matter for market exclusivity?

Featured snippet answer: For Envarsus XR, commercially meaningful protections typically include extended-release tacrolimus formulation patents and associated manufacturing/process patents listed in the Orange Book.

Claim types that most often determine launch timing

• Composition and formulation claims for extended-release delivery.
• Release profile and matrix technology claims.
• Manufacturing or granulation/sieving/compression claims for consistent release.
• Method-of-use claims tied to tacrolimus trough targets or dosing.

Why claim type affects payer substitution

• If protection is mainly formulation-specific, generic sponsors may still need design-around strategies that delay or limit interchangeable acceptance.
• If method-of-use protections exist, conversion can be slower where prescribers must follow legally permitted labeling and therapeutic monitoring protocols.

---

What is the Orange Book status of ENVARSUS XR?

Featured snippet answer: Orange Book status is determined by the listed patents for Envarsus XR and each patent’s expiration dates and exclusivity codes. This status shapes Paragraph IV ANDA strategy and affects when generics can launch.

How to interpret Orange Book entries for underwriting

Key elements for financial modeling:

• Patent expiration dates: identify the latest date that blocks launch for particular claim types.
• Exclusivity flags: map to non-patent exclusivity that can add blocking time.
• Listed dosage forms: confirm whether all strengths are covered equally.

No Orange Book dataset was provided in the prompt; exact listing counts and dates cannot be stated without a source extract.

---

How much revenue does ENVARSUS XR generate and what is the financial trajectory trend?

Featured snippet answer: Envarsus XR’s revenue trend is shaped by conversion-led growth early in a formulary cycle and by net price and mix-driven declines as substitution risk rises. Without company-reported figures for a specific fiscal period, the correct underwriting approach is scenario-based modeling around net revenue per script and script volume.

Commercial trajectory framework used in immunosuppressant brands

Model revenue as:

• Revenue = (scripts or patient prescriptions) × (net price per script)

Then break the net price driver into:

• rebate rate changes,
• payer mix (PBM contract structure),
• channel mix,
• and any wholesaler/chargeback adjustments.

Typical pattern in transplant maintenance drugs

• Script growth during strong payer preference and program ramp.
• Gradual net revenue margin compression as competition expands.
• Step changes around formulary reassessment cycles and new competitor launches.

---

What drives ENVARSUS XR net price, rebates, and gross-to-net?

Featured snippet answer: Net price for Envarsus XR is driven primarily by payer rebate pressure, formulary competitiveness, and patient access constraints such as prior authorization.

High-impact drivers

• PBM contract negotiations: larger rebate demands when competitors gain preferred status.
• Therapeutic interchange policies: whether switching is permitted at pharmacy level or restricted by prescriber.
• Patient copay dynamics: influence adherence and channel pull-through.
• Specialty pharmacy channel terms: discounting and inventory incentives.

Margin implications for financial trajectory

• Revenue can remain stable while net price declines.
• Revenue can decline faster if payer moves from preferred to non-preferred status and limits access.

---

How does ENVARSUS XR perform by geography and payer segment?

Featured snippet answer: US revenue generally dominates due to formulary contracting complexity and payer volume. Global performance depends on local tacrolimus pricing regulation and transplant system procurement practices.

US segment dynamics

• Commercial: PBM-driven formularies and step therapy policies.
• Medicare Part D: coverage tiers, preferred pharmacy networks, and utilization management.
• Specialty pharmacy networks: contracting drives share retention.

Non-US dynamics

• Tender-based hospital procurement can shift share quickly when pricing becomes a primary decision variable.
• Local reimbursement rules can either protect extended-release premiums or compress them to generic levels.

---

What patent litigation or settlements affect ENVARSUS XR market timing?

Featured snippet answer: Patent litigation and any settlement agreements tied to ANDA Paragraph IV filings can delay generic entry and shape the timing of revenue declines.

How to connect litigation to financial outcomes

• If a settlement grants delayed launch dates, revenue typically declines later but not necessarily less sharply.
• If a court decision narrows the asserted claims, generic entry can accelerate even if some patents remain in force.

No litigation docket or settlement record was provided in the prompt; specific case names, dates, and settlement launch windows cannot be stated.

---

How does ENVARSUS XR compare with other tacrolimus formulations on uptake and payer acceptance?

Featured snippet answer: Envarsus XR’s uptake depends on whether payers and transplant centers view extended-release tacrolimus as worth a premium versus immediate-release generics.

Comparison points used by payers and clinicians

• dosing convenience and adherence support,
• expected trough stability variability,
• ability to manage therapeutic monitoring burdens,
• patient tolerance and regimen continuity.

Commercial consequence

If payers believe adherence and trough stability reduce downstream costs, Envarsus XR can sustain preferred placement longer. If those benefits are not monetized in payer models, substitution accelerates.

---

What manufacturing and IP barriers could delay generic or biosimilar substitution?

Featured snippet answer: For extended-release products like Envarsus XR, manufacturing controls and formulation-specific IP can delay generic market entry if design-around is technically difficult or if interchange is clinically constrained.

What matters operationally for generic entrants

• Extended-release matrix technology and release profile reproducibility.
• Stability of pharmacokinetic parameters at steady state.
• Validation for each strength and dosage form.

---

Key Takeaways

• Envarsus XR’s financial trajectory is driven by patient conversion from immediate-release tacrolimus, formulary preference durability, and net price compression as substitution risk rises.
• Competitive pressure is likely to come from generics of tacrolimus immediate-release and from other extended-release tacrolimus products, with payer rebate pressure as the main margin eroder.
• Generic entry timing depends on the Orange Book patent and exclusivity structure and any Paragraph IV challenges and settlements; those factors determine when script loss accelerates.
• Revenue modeling should separate script volume from net price, since channel contracting can shift margins even when scripts hold.
• Underwriting should focus on specialty pharmacy contracting, PBM formulary transitions, and switchability protocols in transplant centers, which typically create the largest step changes in revenue.

---

FAQs

What is the typical market adoption curve for extended-release tacrolimus like Envarsus XR?

Adoption typically grows after formulary preference is established and after transplant centers standardize switching protocols; it then slows as competitors obtain preferred status and payers tighten utilization management.

How do prior authorization requirements influence Envarsus XR scripts?

Stricter prior authorization and step therapy reduce new-to-therapy starts and slow switching, leading to lower prescription conversion rates and faster share erosion.

What metrics best track Envarsus XR financial performance?

Net price per script, specialty pharmacy channel share, rebate rate changes, and patient persistence on therapy are the most predictive metrics.

Do generics of tacrolimus immediate-release automatically displace Envarsus XR?

Not automatically. Displacement depends on interchange policies, therapeutic monitoring practice, and whether prescribers are allowed or incentivized to switch patients.

How do patent settlements change revenue risk?

Settlements can push launch timing later, but they usually do not prevent eventual erosion. The key underwriting input is whether settlement terms delay launch and whether they limit the generic’s ability to claim interchangeability.

---

References

1. FDA Orange Book: Approved Drug Products with Therapeutapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
2. Hatch-Waxman Act and Paragraph IV ANDA framework overview. FDA and statutory sources. https://www.fda.gov/drugs/